



Paris, 29<sup>th</sup> November 2010, 5:45 pm

## Financial Communication Agenda 2011

The indicative agenda of AB Science's financial publications for the fiscal year 2011 is as follow:

- |  |                           |
|--|---------------------------|
| • 2010 full-year sales                     | 28 <sup>th</sup> February |
| • 2010 full-year results presentation      | 23 <sup>rd</sup> March    |
| • 2011 first quarter financial information | 15 <sup>th</sup> April    |
| • General shareholder's meeting            | 23 <sup>rd</sup> May      |
| • 2011 half-year sales and results         | 30 <sup>th</sup> August   |
| • 2011 third quarter financial information | 11 <sup>th</sup> October  |

The Company's communications are released after market.

### About AB Science

Founded in 2001, AB Science is a pharmaceutical company specialising in research, development and commercialisation of protein kinase inhibitors (PKIs), a new class of targeted therapy molecules whose action is to modify signalling pathways within cells. Through these PKIs, the company targets diseases with high unmet medical needs (cancer, inflammatory diseases and central nervous system diseases), in both human and veterinary medicines. Thanks to its extensive research and development capabilities, AB Science has its own portfolio of molecules including masitinib, which has already been registered in veterinary medicine in Europe and is being developed in nine phase 3 studies in human medicine, including three ongoing studies in pancreatic cancer, gastric intestinal tumors (GIST) and mastocytosis.

Further information is available on AB Science's website: [www.ab-science.com](http://www.ab-science.com)



### CONTACTS:

Agnès Villeret (Investors & analysts)

Tel: +33 1 53 32 78 95 - [agnes.villeret@citigate.fr](mailto:agnes.villeret@citigate.fr)

Lucie Larguier (press)

Tel: +33 1 53 32 84 75 - [lucie.larguier@citigate.fr](mailto:lucie.larguier@citigate.fr)

Citigate  
Dewe Rogerson